Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4721-4730 Newer>

The Motley Fool April 3, 2008 Brian Lawler	A Punch to Gilead's Competition A rival compound's bad data signals a better future for Gilead's lead drugs.
The Motley Fool April 3, 2008 Brian Lawler	Will InterMune's Hepatitis C Drug Compete? InterMune announces positive data for its hepatitis C treatment drug.
The Motley Fool April 2, 2008 Michael P. Cecil	Irrational Exuberance for Vytorin and Zetia? Drugmakers Merck and Schering-Plough certainly hoped data from the Enhance study would enhance the value and status of their blockbuster cholesterol-fighting drugs Zetia and Vytorin -- but its results did quite the opposite.
The Motley Fool April 2, 2008 Brian Lawler	A Slate of Data for Exelixis Exelixis will present analyses of study data at the American Society of Clinical Oncology in May for all of its lead cancer-fighting compounds. Investors, take note.
The Motley Fool April 2, 2008 Brian Orelli	Abraxis Tardy, but With a Note Abraxis Bioscience finally gets around to releasing fourth-quarter 2007 financials.
The Motley Fool April 2, 2008 Brian Lawler	Medicines Company Sets Itself Apart Drugmaker Medicines Company wants to distance its angioplasty treatment from heparin.
The Motley Fool April 2, 2008 Brian Lawler	Alexza Establishes a Cash Pipeline Alexza Pharmaceuticals announces that it has signed a deal that will provide it with up to $50 million over the next two years. Investors take note.
The Motley Fool April 2, 2008 Brian Lawler	Bad Timing for AstraZeneca's Good Data AstraZeneca quietly reports a successful clinical study for its cholesterol-lowering lead drug.
The Motley Fool April 2, 2008 Brian Lawler	Following the Drugmaker Formerly Known as Neurochem Neurochem would have been set to hear FDA news on its lead drug candidate Kiacta today, if they had not pulled their marketing application earlier this month.
The Motley Fool April 2, 2008 Brian Lawler	Seattle Genetics Bulks Up Its Pipeline Seattle Genetics biopharmaceutical clinical studies are firing on all cylinders.
<Older 4721-4730 Newer> Return to current articles.